PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS WITH PROTECTION UNTIL 2037 CANADIAN PATENT COMPLETES INTELLECTUAL. | June 1, 2023
PRESS RELEASE AB SCIENCE SUMMARIZES KEY MESSAGES FROM ITS PARTICIPATION TO A PANEL DISCUSSION AT THE 2023 ALS DRUG DEVELOPMENT SUMMIT Paris, 17 May, 2023, 8:00pm CET AB Science SA today. | May 17, 2023
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS RESUMED ITS REVIEW OF THE NEW DRUG SUBMISSION FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS, FOLLOWING ISSUANCE OF A SCREENING ACCEPTANCE. | May 9, 2023
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2022 AND THE KEY EVENTS OF THE PERIOD Financial information and other corporate. | April 28, 2023
PRESS RELEASE SUCCESS OF THE CAPITAL INCREASE BY PRIVATE PLACEMENT FOR AN AMOUNT OF 15 MILLION EUROS Paris, April 24, 2023, 8am CET AB Science S.A. , announces today the success of its capital. | April 24, 2023